

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY .....	1
INTENDED AUDIENCE.....	2
METHODOLOGY .....	2
ANALYST CREDENTIALS.....	2
SCOPE OF REPORT .....	2
INFORMATION SOURCES.....	3
RELATED BCC REPORTS .....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER .....	4
 CHAPTER TWO: SUMMARY.....	 5
SUMMARY.....	5
<i>SUMMARY TABLE U.S. FORECAST OF SPONSORED CLINICAL TRIALS MARKET, THROUGH 2014.....</i>	<i>6</i>
<i>SUMMARY FIGURE U.S. FORECAST OF SPONSORED CLINICAL TRIALS MARKET, 2009-2014 (\$ BILLIONS).....</i>	<i>7</i>
 CHAPTER THREE: OVERVIEW .....	 8
TYPES OF CLINICAL TRIALS .....	8
CLINICAL TRIAL PHASES.....	8
WHO SPONSORS CLINICAL TRIALS? .....	8
<i>TABLE 1 U.S. FORECAST OF SPONSORED CLINICAL TRIALS, THROUGH 2014.....</i>	<i>9</i>
<i>FIGURE 1 U.S. SPONSORED CLINICAL TRIALS MARKET, 2009-2014 (\$ BILLIONS).....</i>	<i>9</i>
<i>FIGURE 2 DRUG DEVELOPMENT TIME LINE.....</i>	<i>10</i>
<i>TABLE 2 PHASES OF THE CLINICAL TRIAL .....</i>	<i>10</i>
PHASE I .....	11
PHASE II.....	11
PHASE III .....	12
PHASE IV/POST-MARKETING TRIALS.....	12
FACTORS AFFECTING STUDY SIZE.....	12
PHYSICIAN AND PATIENT RECRUITMENT .....	13
U.S. GOVERNMENT REGULATIONS .....	14
PHARMACEUTICALS AND BIOLOGICS .....	14
<i>TABLE 3 U.S. LAWS AFFECTING DRUG APPROVAL TIMES.....</i>	<i>14</i>
Additional U.S. Laws Affecting Clinical Trials .....	14
Health Insurance Portability and Accountability Act of 1996 (HIPAA) .....	14
Best Pharmaceuticals for Children Act (BPCA), 2002.....	15

<i>TABLE 4 TOTAL APPROVED ACTIVE MOIETIES WITH NO MARKETING PROTECTION FOR WHICH FDA HAS ISSUED A WRITTEN REQUEST</i> .....	16
FOOD AND DRUG ADMINISTRATION (FDA).....	16
Background.....	16
Center for Biologics Evaluation and Research (CBER).....	17
CBER and Bioterrorism.....	18
Center for Drug Evaluation and Research (CDER).....	18
CDER and Bioterrorism .....	18
Critical Path Initiative (CPI).....	19
MEDICAL DEVICES .....	19
Center for Devices and Radiologic Health (CDRH).....	19
Articles Subject to Medical Device Amendments.....	19
Classification of Devices (General Section 513).....	20
• Class I—General Controls.....	20
• Class II—Special Controls.....	20
• Class III.....	21
Expedited Review.....	21
<i>FIGURE 3 NEW DRUG DEVELOPMENT</i> .....	21
<i>TABLE 5 CDER APPROVAL TIMES FOR PRIORITY AND STANDARD NDAS AND BLAS, CALENDAR YEARS, 1993 2008</i> .....	22
Expedited Development and Review .....	22
<i>TABLE 6 FIRST CYCLE APPROVAL RATE FOR OVERALL STUDY COHORT BY YEAR, 2002-2007</i> .....	23
Subpart E.....	23
Accelerated Approval (Subpart H).....	24
Priority Review .....	24
Fast Track.....	24
<i>TABLE 7 NUMBER AND TOTAL APPROVAL TIME (IN MONTHS) OF APPROVED NDAS AND BLAS, BY FISCAL YEAR OF SUBMISSION AND BY REVIEW PROCEDURE</i> .....	25
Pediatrics .....	25
U.S. LITIGATION AND CLINICAL TRIALS.....	25
<i>TABLE 8 INSURANCE COMPANIES OFFERING CLINICAL TRIAL LIABILITY INSURANCE</i> .....	26
INVESTIGATIONAL REVIEW BOARD (IRB).....	26
EUROPEAN REGULATIONS.....	27
JAPANESE REGULATIONS.....	28
GLOBAL REGULATORY STANDARDS.....	28
INTERNATIONAL CONFERENCE OF HARMONIZATION (ICH).....	28
International Conference of Harmonization ... (Continued).....	29
CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING .....	30

MANAGING CLINICAL TRIALS .....	30
CONTRACT RESEARCH ORGANIZATIONS (CROS).....	31
CLINICAL TRIAL RESEARCH THERAPEUTIC AREAS .....	31
<i>FIGURE 4 PHRMA MEMBER R&amp;D FUNDING BY THERAPEUTIC</i>	
<i>CATEGORY, 2010 (% SHARE) .....</i>	<i>32</i>
<i>TABLE 9 BEST-SELLING PHARMACEUTICAL DRUGS WORLDWIDE,</i>	
<i>2009 (\$ BILLIONS).....</i>	<i>33</i>
TRENDS IN CLINICAL TRIALS.....	33
ELECTRONIC DATA CAPTURE (EDC) .....	33
CLINICAL TRIAL COSTS .....	34
FACTORS INFLUENCING CLINICAL TRIAL COSTS.....	34
Factors Increasing Clinical Trial Costs .....	34
Factors Increasing Clinical ... (Continued) .....	35
Factors Decreasing Clinical Trial Costs .....	36
RECENT AND FUTURE TRENDS IN CLINICAL TRIAL	
PROCESSES .....	36
RESEARCH AND DEVELOPMENT BUDGETS .....	36
<i>TABLE 10 INVESTMENT IN R&amp;D AS A PERCENT OF SALES,</i>	
<i>PHARMACEUTICAL INDUSTRY, THROUGH 2014 (%).....</i>	<i>37</i>
<i>TABLE 11 INVESTMENT IN R&amp;D AS A PERCENT OF SALES,</i>	
<i>PHARMACEUTICAL INDUSTRY, THROUGH 2014, PHRMA</i>	
<i>MEMBERS, (%).....</i>	<i>37</i>
FUNDING CLINICAL TRIALS .....	38
<i>TABLE 12 TOTAL R&amp;D SPENDING BY SOURCE, THROUGH 2014 (\$</i>	
<i>BILLIONS).....</i>	<i>39</i>
<i>TABLE 13 ESTIMATES OF NIH RESEARCH FUNDING FOR TOP 50</i>	
<i>CONDITIONS AND DISEASE CATEGORIES, RESEARCH/DISEASE</i>	
<i>AREAS, THROUGH 2010 (\$ MILLIONS/ROUNDED) .....</i>	<i>40</i>
BIOTECH/PHARMACEUTICAL COMPANIES.....	41
<i>TABLE 14 U.S. MARKET FORECAST OF REGISTERED CLINICAL</i>	
<i>TRIALS SPONSORED BY INDUSTRY BY PHASE, THROUGH 2014</i>	
<i>(RECRUITING SUBJECTS).....</i>	<i>42</i>
NATIONAL INSTITUTES OF HEALTH AND OTHER	
FEDERAL AGENCIES OF THE FEDERAL GOVERNMENT .....	42
<i>TABLE 15 U.S. MARKET FORECAST OF REGISTERED CLINICAL</i>	
<i>TRIALS SPONSORED BY FEDERAL GOVERNMENT BY PHASE,</i>	
<i>THROUGH 2014 (RECRUITING SUBJECTS) .....</i>	<i>43</i>
PRIVATE ORGANIZATIONS, UNIVERSITIES, AND	
SPECIALTY GROUPS.....	43
<i>TABLE 16 U.S. MARKET FORECAST OF REGISTERED CLINICAL</i>	
<i>TRIALS SPONSORED BY UNIVERSITIES OR OTHER</i>	
<i>ORGANIZATIONS BY PHASE, THROUGH 2014 (RECRUITING</i>	
<i>SUBJECTS).....</i>	<i>44</i>

<i>TABLE 17 TOP 25 FOUNDATIONS AWARDING U.S.-FOCUSED GRANTS FOR GLOBAL HEALTH, RANKED BY NUMBER OF GRANTS AND DOLLAR AMOUNT, 2008</i> .....	44
Private Organizations, Universities... (Continued) .....	45

CHAPTER FIVE: CLINICAL TRIAL PIPELINES AND TECHNOLOGY

TRENDS .....	46
DRUGS BY SYSTEM.....	46
CARDIOVASCULAR .....	46
PhRMA Facts .....	46
PhRMA Facts (Continued).....	47
<i>TABLE 18 SELECTED CARDIOVASCULAR THERAPEUTICS IN DEVELOPMENT, 2010</i> .....	48
CANCER.....	49
PhRMA Facts .....	49
PhRMA Facts (Continued).....	50
<i>TABLE 19 SELECTED ANTICANCER DRUGS IN DEVELOPMENT, 2010</i> .....	51
CENTRAL NERVOUS SYSTEM.....	51
PhRMA Facts .....	52
<i>TABLE 20 SELECTED CENTRAL NERVOUS SYSTEM THERAPEUTICS IN DEVELOPMENT, 2010</i> .....	53
INFECTION .....	54
INFLAMMATION .....	54
RESPIRATORY .....	55
<i>TABLE 21 CDER PRIORITY DRUG AND BIOLOGIC APPROVALS: CALENDAR YEAR 2009</i> .....	55
<i>TABLE 21 (CONTINUED)</i> .....	56
DEVICES.....	56
BIOMEMS .....	56
STENTS.....	56
IMPLANTS .....	57
<i>TABLE 22 MEDICAL DEVICES CLEARED OR APPROVED BY FDA IN 2010</i> .....	57
<i>TABLE 22 (CONTINUED)</i> .....	58
<i>TABLE 23 TOP MEDICAL DEVICE COMPANIES, IN TERMS OF 2009 REVENUES (\$ MILLIONS)</i> .....	58
BIOTECHNOLOGY VERSUS PHARMACEUTICAL.....	59
BIOLOGICS .....	60
<i>TABLE 24 SELECTED BIOLOGICS IN DEVELOPMENT, 2010</i> .....	60
<i>TABLE 25 BIOTECHNOLOGY CANDIDATES IN DEVELOPMENT BY MODALITY, 2008</i> .....	61
<i>TABLE 26 BIOTECHNOLOGY CANDIDATES IN DEVELOPMENT BY INDICATION, 2008</i> .....	62
TECHNOLOGIES .....	62

<i>TABLE 27 NUMBER OF CLINICAL TRIALS USING NEW TECHNOLOGIES, THROUGH 2014</i> .....	63
<i>TABLE 28 NEW TECHNOLOGIES AND PROJECTED EFFECT ON CLINICAL TRIALS</i> .....	64
ANTISENSE .....	64
APOPTOSIS .....	65
BIOCHIPS/MICROARRAYS .....	65
BIOINFORMATICS .....	65
BIOPROCESSORS .....	65
CELLS AND CELL SIGNALING .....	66
CELL THERAPY (I.E., STEM CELLS, TISSUE REPAIR).....	66
CHEMICAL GENOMICS .....	67
CYTOMICS.....	67
ELECTRONIC DATA CAPTURE AND E-SUBMISSION .....	67
GENE THERAPY .....	67
GENOMICS.....	67
NOVEL DRUG DELIVERY SYSTEMS .....	68
PROTEOMICS.....	68
Four-part Definition of Proteomics .....	68
THERANOSTICS .....	69
TRANSGENICS .....	69
NANOTECHNOLOGY .....	69
NATURAL SOURCES .....	69
BIOMARKERS CONSORTIUM .....	69
NIH Public-Private Partnerships Policy Statement .....	69
FACTORS INFLUENCING DRUG DEVELOPMENT .....	70
<i>FIGURE 5 FACTORS INFLUENCING DRUG DEVELOPMENT</i> .....	71
EPIDEMIOLOGICAL TRENDS .....	71
LEGISLATION.....	71
NEW TECHNOLOGIES .....	72
BIOTERRORISM .....	72
 CHAPTER SIX: CONTRACT RESEARCH ORGANIZATIONS AND GLOBALIZATION.....	73
CONTRACT RESEARCH ORGANIZATIONS AND GLOBALIZATION .....	73
CONTRACT RESEARCH ORGANIZATIONS ... (CONTINUED) .....	74
ASSOCIATION OF CLINICAL RESEARCH ORGANIZATIONS	
FACTS.....	75
ASSOCIATION OF CLINICAL RESEARCH ... (CONTINUED) .....	76
<i>TABLE 29 TOP TEN CROS BY REVENUES, 2009</i> .....	77
GLOBALIZATION .....	77
<i>TABLE 30 CLINICAL TRIALS WITH OPEN ENROLLMENT BY REGION, JULY 2010</i> .....	78
OUTSOURCING CLINICAL TRIALS TO FOREIGN COUNTRIES .....	78

<i>TABLE 31 CLINICAL TRIALS RECRUITING SUBJECTS IN TARGETED COUNTRIES, JULY 2010</i> .....	78
<i>TABLE 31 (CONTINUED)</i> .....	79
<i>TABLE 32 AVERAGE COST PER PATIENT FOR TRIALS IN THE U.S., CANADA, AND WESTERN EUROPE FOR ALL THERAPEUTIC AREAS, THROUGH 2014 (\$)</i> .....	80
Advantages .....	80
Costs .....	80
<i>TABLE 33 AVERAGE COST PER PATIENT FOR TRIALS IN REDUCED COST COUNTRIES, THROUGH 2014 (\$)</i> .....	81
Efficiency .....	81
Disadvantages.....	81
Sociopolitical Issues .....	82
BRAZIL.....	82
Patent Protection.....	82
Pharmaceutical and Clinical Trial Registration .....	82
Clinical Trials .....	82
<i>TABLE 34 BRAZILIAN DOMESTIC PHARMACEUTICAL COMPANIES</i> .....	83
CHINA .....	83
Patent Protection.....	83
Pharmaceutical and Clinical Trial Registration .....	83
Clinical Trials .....	83
Leading Chinese Pharmaceutical Companies.....	84
Beijing Double-Crane Pharmaceutical (DCPC).....	84
Northeast General Pharmaceutical .....	84
Sanjiu Medical and Pharmaceutical Co., Ltd. ....	84
C & O Pharmaceutical Technology Holdings Ltd.....	84
Shijiazhuang Pharma Group.....	84
Wuxi Pharmatech .....	84
Harbin Pharmaceutical Group Co.....	85
INDIA .....	85
Advantages .....	85
Disadvantages.....	85
Key Points for Doing Clinical Studies in India .....	86
<i>TABLE 35 INDIAN DOMESTIC PHARMACEUTICAL PRODUCERS</i> .....	86
<i>TABLE 36 INDIA'S DOMESTIC PHARMACEUTICAL MARKET (12 MONTHS ENDED JANUARY 2009)</i> .....	87
<i>TABLE 37 TOP FIVE BIOTECHNOLOGY COMPANIES IN INDIA</i> .....	87
ROMANIA .....	87
Patent Protection.....	88
RUSSIA.....	88
Patent Protection.....	88
<i>TABLE 38 LEADING RUSSIAN PHARMACEUTICAL COMPANIES</i> .....	88
CHAPTER SEVEN: BIOTECHNOLOGY COMPANIES .....	89

ACTELION PHARMACEUTICALS, LTD .....	89
<i>TABLE 39 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	89
ALEXION PHARMACEUTICALS, INC. ....	90
<i>TABLE 40 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	90
ALLERGAN, INC.....	91
<i>TABLE 41 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	91
<i>TABLE 41 (CONTINUED)</i> .....	92
ALSERES PHARMACEUTICALS, INC. ....	92
<i>TABLE 42 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	92
AMGEN .....	93
<i>TABLE 43 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	93
<i>TABLE 43 (CONTINUED)</i> .....	94
ARQULE.....	95
<i>TABLE 44 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	95
ARRAY BIOPHARMA .....	96
<i>TABLE 45 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	96
AVANIR PHARMACEUTICALS.....	97
<i>TABLE 46 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	97
BAXTER BIOSCIENCE .....	98
<i>TABLE 47 SAMPLE OF BAXTER'S CLINICAL TRIALS IN PROGRESS,</i> <i>AUGUST 2010</i> .....	98
<i>TABLE 47 (CONTINUED)</i> .....	99
<i>TABLE 47 (CONTINUED)</i> .....	100
BIOCON .....	100
<i>TABLE 48 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	101
BIOGEN IDEC.....	101
<i>TABLE 49 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	101
<i>TABLE 49 (CONTINUED)</i> .....	102
CELGENE CORP.....	102
<i>TABLE 50 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	103
CELL THRAPEUTICS .....	103
<i>TABLE 51 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	104
CELLDEX THERAPEUTICS.....	104
<i>TABLE 52 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	105
CEPHALON, INC. ....	105
<i>TABLE 53 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	106
CSL BEHRING (CSL, LTD) .....	106
<i>TABLE 54 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	107
CYTOKINETICS.....	107
<i>TABLE 55 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	108
DENDREON .....	108
<i>TABLE 56 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	109
DYNAVAX TECHNOLOGIES .....	110
<i>TABLE 57 CLINICAL PIPELINE AS OF 12/31/2009</i> .....	110

ELAN.....	110
TABLE 58 CLINICAL PIPELINE AS OF 12/31/2009.....	111
ENZON PHARMACEUTICALS.....	111
TABLE 59 CLINICAL PIPELINE AS OF 12/31/2009.....	112
EPICEPT CORPORATION .....	112
TABLE 60 CLINICAL PIPELINE AS OF 12/31/2009.....	113
GENENTECH .....	113
TABLE 61 CLINICAL PIPELINE AS OF 12/31/2009.....	114
TABLE 61 (CONTINUED).....	115
GENZYME .....	116
TABLE 62 CLINICAL PIPELINE AS OF 12/31/2009.....	117
GILEAD.....	117
TABLE 63 CLINICAL PIPELINE AS OF 12/31/2009.....	118
GTC BIOTHERAPEUTICS, INC. ....	119
TABLE 64 CLINICAL PIPELINE AS OF 12/31/2009.....	119
GTX.....	120
TABLE 65 CLINICAL PIPELINE AS OF 12/31/2009.....	120
HUMAN GENOME SCIENCES .....	120
TABLE 66 CLINICAL PIPELINE AS OF 12/31/2009.....	121
IDERA PHARMACEUTICALS, INC. ....	121
TABLE 67 CLINICAL PIPELINE AS OF 12/31/2009.....	122
IMMUNOGEN, INC. ....	122
TABLE 68 CLINICAL PIPELINE AS OF 12/31/2009.....	123
IMMUNOMEDICS, INC.....	123
TABLE 69 CLINICAL PIPELINE AS OF 12/31/2009.....	124
LORUS THERAPEUTICS INC.....	124
TABLE 70 CLINICAL PIPELINE AS OF 12/31/2009.....	124
MAXYGEN.....	125
TABLE 71 CLINICAL PIPELINE AS OF 12/31/2009.....	125
MYRIAD PHARMACEUTICALS, INC.....	125
TABLE 72 CLINICAL PIPELINE AS OF 12/31/2009.....	126
NOVO NORDISK A/S.....	126
TABLE 73 CLINICAL PIPELINE AS OF 12/31/2009.....	127
NPS PHARMACEUTICALS, INC.....	127
TABLE 74 CLINICAL PIPELINE AS OF 12/31/2009.....	128
REPLIGEN CORPORATION.....	128
TABLE 75 CLINICAL PIPELINE AS OF 12/31/2009.....	129
SANGAMO BIOSCIENCES, INC. ....	129
TABLE 76 CLINICAL PIPELINE AS OF 12/31/2009.....	129
SEATTLE GENETICS, INC.....	130
TABLE 77 CLINICAL PIPELINE AS OF 12/31/2009.....	130
TALECRIS BIOTHERAPEUTICS, INC. ....	131
TABLE 78 CLINICAL PIPELINE AS OF 12/31/2009.....	131
UCB SA .....	132



TABLE 79 CLINICAL PIPELINE AS OF 12/31/2009.....	132
URIGEN PHARMACEUTICALS, INC.....	133
TABLE 80 CLINICAL PIPELINE AS OF 12/31/2009.....	133
VERTEX PHARMACEUTICALS INCORPORATED.....	133
TABLE 81 CLINICAL PIPELINE AS OF 12/31/2009.....	134
VICAL, INCORPORATED .....	134
TABLE 82 CLINICAL PIPELINE AS OF 12/31/2009.....	135
XOMA, LTD.....	135
TABLE 83 CLINICAL PIPELINE AS OF 12/31/2009.....	136
 CHAPTER EIGHT: PHARMACEUTICAL COMPANIES .....	 137
ABBOTT LABORATORIES.....	137
TABLE 84 CLINICAL PIPELINE HIGHLIGHTS AS OF 8/2010 .....	137
ASTRAZENECA PLC .....	138
TABLE 85 CLINICAL PIPELINE AS OF 12/31/2009.....	138
TABLE 85 (CONTINUED).....	139
TABLE 85 (CONTINUED).....	140
TABLE 85 (CONTINUED).....	141
BAYER SCHERING PHARMA AG.....	141
TABLE 86 PHASE II/III CLINICAL PIPELINE AS OF 12/31/2009 .....	142
TABLE 86 (CONTINUED).....	143
BOEHRINGER INGELHEIM GMBH .....	143
TABLE 87 CLINICAL PIPELINE AS OF 12/31/2009.....	144
BRISTOL-MYERS SQUIBB COMPANY .....	144
TABLE 88 CLINICAL PIPELINE, SELECTED PHASE I/II CANDIDATES AS OF 12/31/2009 .....	145
TABLE 88 (CONTINUED).....	146
TABLE 89 INVESTIGATIONAL CANDIDATES IN PHASE III CLINICAL TRIALS .....	146
ELI LILLY AND COMPANY .....	147
TABLE 90 CLINICAL PIPELINE HIGHLIGHTS AS OF 8/2010 .....	147
GLAXOSMITHKLINE PLC .....	148
TABLE 91 CLINICAL PIPELINE AS OF 12/31/2009.....	148
TABLE 91 (CONTINUED).....	149
TABLE 91 (CONTINUED).....	150
TABLE 91 (CONTINUED).....	151
TABLE 91 (CONTINUED).....	152
JOHNSON & JOHNSON .....	152
TABLE 92 SELECTED PHASE III CLINICAL PIPELINE AS OF 12/31/2009 .....	153
MERCK & CO., INC. ....	154
TABLE 93 CLINICAL PIPELINE AS OF 12/31/2009.....	154
TABLE 93 (CONTINUED).....	155
MERCK SERONO.....	155
TABLE 94 CLINICAL PIPELINE AS OF 12/31/2009.....	156

NOVARTIS AG .....	156
TABLE 95 CLINICAL PIPELINE AS OF 12/31/2009.....	157
TABLE 95 (CONTINUED).....	158
TABLE 95 (CONTINUED).....	159
TABLE 95 (CONTINUED).....	160
TABLE 95 (CONTINUED).....	161
PFIZER, INC.....	161
TABLE 96 CLINICAL PIPELINE AS OF 12/31/2009.....	162
TABLE 96 (CONTINUED).....	163
TABLE 96 (CONTINUED).....	164
TABLE 96 (CONTINUED).....	165
ROCHE.....	165
TABLE 97 CLINICAL PIPELINE AS OF 12/31/2009.....	166
TABLE 97 (CONTINUED).....	167
TABLE 97 (CONTINUED).....	168
SANOFI-AVENTIS .....	168
TABLE 98 CLINICAL PIPELINE AS OF 12/31/2009.....	169
TABLE 98 (CONTINUED).....	170
TAKEDA PHARMACEUTICAL COMPANY LIMITED .....	171
TABLE 99 CLINICAL PIPELINE AS OF 12/31/2009.....	172
TABLE 99 (CONTINUED).....	173
TABLE 99 (CONTINUED).....	174
TABLE 99 (CONTINUED).....	175
CHAPTER NINE: MEDICAL EQUIPMENT AND DEVICES .....	176
TABLE 100 MEDICAL EQUIPMENT AND DEVICE COMPANIES IN THE U.S. WITH ANNUAL REVENUES EXCEEDING \$1 BILLION .....	176
TABLE 100 (CONTINUED).....	177
TABLE 100 (CONTINUED).....	178
TABLE 100 (CONTINUED).....	179
CHAPTER TEN: CLINICAL RESEARCH ORGANIZATIONS.....	180
TOP 10 CROS.....	180
TABLE 101 TOP 10 CROS BY REVENUE (ACCOUNTED FOR MORE THAN 50% OF TOTAL INDUSTRY REVENUE IN 2008/2009).....	180
SECONDARY CROS (ALPHABETICAL ORDER).....	180
TABLE 102 SECONDARY CROS (ALPHABETICAL ORDER) .....	180
TABLE 102 (CONTINUED).....	181
NICHE CRO SPECIALIZED BY REGION OR THERAPEUTIC FOCUS (ALPHABETICAL ORDER) .....	181
TABLE 103 NICHE CRO SPECIALIZED BY REGION OR THERAPEUTIC FOCUS (ALPHABETICAL ORDER).....	181
TABLE 103 (CONTINUED).....	182
TABLE 103 (CONTINUED).....	183
TABLE 103 (CONTINUED).....	184

<i>TABLE 103 (CONTINUED)</i> .....	185
<i>TABLE 103 (CONTINUED)</i> .....	186